Updates are available Erratum dated 2017-09-15
Click to view Erratum: https://doi.org/10.1038/nrc.2017.85
-
Authors
Byrne, Annette T.
Alférez, Denis G.
Amant, Frédéric
Annibali, Daniela
Arribas, Joaquín
Biankin, Andrew V.
Bruna, Alejandra
Budinská, Eva
Caldas, Carlos
Chang, David K.
Clarke, Robert B.
Clevers, Hans
Coukos, George
Dangles-Marie, Virginie
Eckhardt, S. Gail
Gonzalez-Suarez, Eva
Hermans, Els
Hidalgo, Manuel
Jarzabek, Monika A.
de Jong, Steven
Jonkers, Jos
Kemper, Kristel
Lanfrancone, Luisa
Mælandsmo, Gunhild Mari
Marangoni, Elisabetta
Marine, Jean-Christophe
Medico, Enzo
Norum, Jens Henrik
Palmer, Héctor G.
Peeper, Daniel S.
Pelicci, Pier Giuseppe
Piris-Gimenez, Alejandro
Roman-Roman, Sergio
Rueda, Oscar M.
Seoane, Joan
Serra, Violeta
Soucek, Laura
Vanhecke, Dominique
Villanueva, Alberto
Vinolo, Emilie
Bertotti, Andrea
Trusolino, Livio
- License Information
-
More Information
Article History
First Online: 20 January 2017
Change Date: 15 September 2017
Change Type: Erratum
Change Details: In the online html version of this article, Joan Seoane's affiliations were not correct. He is also a member of the EurOPDX Consortium and is at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain. This is correct in the print and PDF versions of the article.
Competing interests
: Grants from Celgene and Boehringer-Ingelheim, honoraria from Roche and Genentech, consultancy for Roche, Genentech, Novartis and Sanofi-Aventis (G.C.), consultancy for Oncodesign and funding by Novartis (S.R.R.), founder of the spin-off Xenopat S.L. (A.V.). The other authors declare no competing interests.
